abstract |
This invention relates to the use of selective cyclic guanosine 3', 5'-monophosphate type five (cGMP PDE5} inhibitors (hereinafter PDE5 inhibitors), including in particular the compound sildenafil, for the treatment of or prevention of scarring or fibrosis in tissue. |